10x Genomics sits in a rare and uncomfortable spot — the Street is rushing to lift price targets while short interest continues to grind higher, and the stock fell 5.4% on Tuesday to $37.83, still below where most of those new targets were set.
The analyst activity this week is hard to ignore. Citigroup raised its target from $24 to $45 on July 8, a near-doubling in one move, while keeping a Neutral rating. Piper Sandler did something similar the week before — target from $20 to $42, again Neutral. Barclays, the most constructive voice among the group, lifted to $40 with an Overweight in late June. The pattern is consistent: every firm is raising numbers, none are upgrading conviction. The consensus mean target has run to $30.92 — which, notably, sits below the current stock price of $37.83, suggesting the Street's formal targets have been outpaced by the rally rather than leading it. Bulls point to accelerating consumables revenue and a 5-19x per-platform growth runway by 2027. Bears counter that the company posted double-digit pricing pressure in 2024, missed Q4 estimates, and cut guidance in June — with no meaningful recovery expected before 2027.
Short positioning has continued to build even as targets climbed. Short interest reached 18.9% of free float as of July 7 — up 3.3% on the week and 7.6% over the past month — extending the rebuild that was flagged in the prior note. The FINRA fortnightly count puts 22.1 million shares short with 6.8 days to cover, making this one of the more heavily shorted names in the life-science tools space. Crucially, the borrow market gives shorts no reason to cover. Availability is generous at 597% — well inside the normal range and tighter than the near-1,000% readings of late June, but not close to distressed territory. Cost to borrow has edged up to 0.45%, a four-week high, but remains negligible. The combination of high short interest and loose borrow conditions means bears can maintain and add to positions at minimal cost.
Options positioning is neutral, reinforcing the picture of a market waiting rather than committed. The put/call ratio at 0.29 is virtually in line with its 20-day average of 0.28, and the z-score of 0.10 signals no directional tilt. The 52-week range for the PCR runs from 0.06 to 0.43, and the current reading sits near the floor — meaning options traders have shown far more defensiveness in the past than they are now. The ORTEX short score has nudged up to 62.9 from 58.9 ten days ago, a steady drift higher that corroborates the gradual accumulation narrative. The 30-day EPS momentum factor ranks in the 96th percentile, a notable positive; but the 90-day EPS momentum ranks in the 1st percentile, flagging how rapidly that sentiment reversed.
On the ownership side, the most meaningful institutional move in the recent data is FMR adding 5.8 million shares to reach 14.7% of the company — a significant position build. ARK Investment Management holds 9.2%, adding modestly. Founder and CEO Serge Saxonov sold roughly 30,000 shares across multiple transactions on June 22, all around $33–$36, pocketing just over $1 million in total. The CSO and CFO also sold in late May. These are small in percentage terms, but consistent insider selling into a rising stock — alongside rising short interest — reflects a real tension between institutional accumulation and founder distribution.
Earnings history adds a cautionary note: the last two reported quarters each produced next-day drops of 3.5% and 5.0% respectively, with five-day losses of 9.7% and 5.4% following. The next print is scheduled for August 7 — just four weeks out — and given the pattern, how TXG responds to that event is likely to determine whether the current short base proves prescient or gets squeezed out.
See the live data behind this article on ORTEX.
Open TXG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
